- Home
- SNY vs BUD Comparison
SNY vs BUD Comparison
Compare SNY & BUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- BUD
- Stock Information
- Founded
- SNY 1994
- BUD 1366
- Country
- SNY France
- BUD Belgium
- Employees
- SNY N/A
- BUD N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- BUD Beverages (Production/Distribution)
- Sector
- SNY Health Care
- BUD Consumer Staples
- Exchange
- SNY Nasdaq
- BUD Nasdaq
- Market Cap
- SNY 127.2B
- BUD 133.5B
- IPO Year
- SNY N/A
- BUD N/A
- Fundamental
- Price
- SNY $49.37
- BUD $70.50
- Analyst Decision
- SNY Buy
- BUD Strong Buy
- Analyst Count
- SNY 2
- BUD 4
- Target Price
- SNY $62.50
- BUD $72.00
- AVG Volume (30 Days)
- SNY 2.4M
- BUD 2.0M
- Earning Date
- SNY 07-24-2025
- BUD 05-08-2025
- Dividend Yield
- SNY 4.48%
- BUD 1.49%
- EPS Growth
- SNY 39.56
- BUD 45.11
- EPS
- SNY 5.45
- BUD 3.38
- Revenue
- SNY $48,817,552,946.00
- BUD $58,849,000,000.00
- Revenue This Year
- SNY $3.39
- BUD $1.98
- Revenue Next Year
- SNY $7.05
- BUD $4.52
- P/E Ratio
- SNY $17.77
- BUD $20.12
- Revenue Growth
- SNY N/A
- BUD N/A
- 52 Week Low
- SNY $45.80
- BUD $45.94
- 52 Week High
- SNY $60.12
- BUD $70.75
- Technical
- Relative Strength Index (RSI)
- SNY 38.24
- BUD 70.66
- Support Level
- SNY $51.80
- BUD $69.71
- Resistance Level
- SNY $52.41
- BUD $70.72
- Average True Range (ATR)
- SNY 0.83
- BUD 0.68
- MACD
- SNY -0.06
- BUD 0.16
- Stochastic Oscillator
- SNY 16.44
- BUD 95.62
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.